Clinical trial · no report yet · Phase 1/Phase 2
IDeate-PanTumor01
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
- NCT04145622 ↗
- Active, not recruiting
- Daiichi Sankyo
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 4 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase I/II, Two-Part, Multicenter First-in-Human Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Subjects With Advanced Solid Malignant Tumors (IDeate-PanTumor01)
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Advanced Solid Tumor; Malignant Solid Tumor
- Interventions
- Ifinatamab deruxtecan (I-DXd)
- Arms
- Dose escalation · Experimental
- Dose expansion · Experimental
- Enrollment
- 247
- Primary outcomes
- Evaluate the incidence of dose-limiting toxicities (DLTs)
- Evaluate the incidence of adverse events (AEs)
- Investigate the antitumor activity of ifinatamab deruxtecan (I-DXd)
- Sponsor
- Daiichi Sankyo with Merck Sharp & Dohme LLC
- Start
- Nov 3, 2019
- Primary completion
- Apr 30, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04145622 · updated Oct 6, 2026
Publications
linked from the registry- Johnson ML, Patel MR, Falchook GS, Koyama T, Gutierrez M, Awad MM, Piha-Paul SA, Friedman CF, Satoh T, Okamoto N, Singh J, Yoshizuka N, Windish HP, Qian M, Tran BP, Doi T. Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial. Lancet Oncol. 2026 Apr;27(4):491-501. doi: 10.1016/S1470-2045(25)00733-8. PubMed 41926962